{"filings":[{"id":2106369,"accession_number":"0000730464-26-000037","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-08-06T20:19:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Covista reports Q4 and FY 2026 results; press release content not provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Covista issued a press release on August 6, 2026, announcing Q4 and full year fiscal 2026 results.","The press release text was not included in the provided filing excerpt.","No specific financial figures or guidance are available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1913639,"accession_number":"0001104659-26-087540","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-07-28T20:15:14+00:00","items":["5.02","9.01"],"status":"ready","headline":"Covista appoints Emily Chiu and Leslie Storms to Board, effective Aug 17, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Emily Chiu (former CEO of Novo Platform) and Leslie Storms (veterinary health network leader) as independent directors, effective Aug 17, 2026.","Board size increased from 10 to 12 members; both will stand for re-election at 2026 annual meeting.","Each receives prorated RSU grant of ~$32,986 on Aug 17, plus $150,000 equity retainer after annual meeting and $85,000 annual cash retainer.","Appointments support Covista's 'Purpose at Scale' three-year growth strategy to address healthcare workforce challenges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98572,"accession_number":"0000730464-26-000021","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Covista Q3 revenue up 4.5%, enrollment over 100k; raises FY2026 revenue and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $487M (+4.5% YoY); adjusted EPS $1.98 vs $1.92; GAAP EPS $1.20 vs $1.59.","Total enrollment 100,585 (+6.8% YoY); Chamberlain returned to positive enrollment growth; Walden +12.3%.","Raised FY2026 guidance: revenue $1,930-1,945M (prev $1,900-1,940M); adjusted EPS $7.95-8.15 (prev $7.80-8.00).","Repurchased $66M shares in Q3; refinanced $510M Term Loan B due 2033; net leverage 0.7x.","Medical schools 97% first-time residency; AI certificates w/ Google Cloud enrolled 4,000+ learners."],"consensus_eps_estimate":null,"consensus_eps_actual":4.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":1452703000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98571,"accession_number":"0000730464-26-000015","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Covista targets 7-10% revenue CAGR, >120k enrollment by FY2029 in new strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Financial targets through FY2029: revenue CAGR 7-10%, adjusted EPS CAGR 10-14%, enrollment >120,000.","Appointed Dr. Cheryl Holmes as Dean of Ross University School of Medicine (RUSM) effective March 2026.","Became founding member of Alliance for Advancing Rural Healthcare (AARH) to support federal Rural Health Transformation.","FY2026 guided revenue midpoint $1,920M and adjusted EPS midpoint $7.90; Q3 earnings call on May 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114139,"accession_number":"0000730464-26-000010","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Covista enters $510M term loan refinancing, redeems $405M senior notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $510M 2026 Term Loans issued under amended credit agreement, maturing March 2, 2033.","Proceeds used to refinance existing term loans and redeem $404.95M of 5.50% Senior Secured Notes due 2028.","Interest rate: Term SOFR + 2.25% (0.75% floor) or alternate base rate + 1.25%, a 0.50% margin reduction.","Notes redemption completed on March 2, 2026; Indenture fully satisfied and discharged.","Amendment executed with Morgan Stanley Senior Funding as administrative agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114138,"accession_number":"0000730464-26-000007","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Covista unveils 'Purpose at Scale' 3-year plan; FY26 reaffirmed, ticker to CVSA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Introduces 'Purpose at Scale' strategy for FY27-29 targeting revenue growth 6-11% and adj. EPS growth 9-16% annually.","Reaffirms FY26 guidance: revenue $1.9B-$1.94B (+6-8.5% YoY) and adj. EPS $7.80-$8.00 (+17-20% YoY).","Partners with GE Healthcare HelloAI for AI fluency and SAIC for rural healthcare workforce solutions.","Stock ticker changes to CVSA effective Feb 24, 2026 on NYSE; serves 97,000+ students vs 76,000 in June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114137,"accession_number":"0001104659-26-011611","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Adtalem rebrands as Covista, ticker CVSA; launches research platform and investor day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from Adtalem Global Education to Covista Inc. effective Feb 5, 2026; NYSE ticker changes to CVSA effective Feb 24.","Largest U.S. healthcare educator: 97,000+ students, 385,000 alumni, 24,000 graduates/year (10% of nurses).","Released Covista Care Capacity Monitor (Gallup): 702,000 monthly healthcare job vacancies vs 306,000 unemployed workers.","Investor Day on Feb 24 to discuss long-term strategy; launches Covista Open Doors multi-year impact commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114136,"accession_number":"0000730464-26-000003","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem reports Q2 FY2026 results; financial details not included in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued a press release on January 28, 2026, announcing second quarter fiscal 2026 academic, operating and financial results.","Exhibit 99.1 (press release) was referenced but not provided; no specific financial figures are available from this summary.","Investors should review the full press release for revenue, earnings, and guidance data."],"consensus_eps_estimate":null,"consensus_eps_actual":3.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":965673000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130521,"accession_number":"0000730464-25-000063","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adtalem completes $150M buyback, authorizes new $750M repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed $150M accelerated share repurchase program; repurchased 1.6M shares.","Board authorized new $750M share repurchase program through December 2028.","Since Feb 2022, returned $913M to shareholders: 17.2M shares at avg $52.94 (30% reduction in shares).","Debt reduced by $1.1B since Walden University acquisition (Aug 2021), to $508.4M as of Oct 31, 2025.","Outstanding shares as of Dec 10, 2025: 34.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130520,"accession_number":"0000730464-25-000060","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adtalem shareholders elect 10 directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with overwhelming support; votes for ranged from 30.9M to 31.7M.","Ratification of PricewaterhouseCoopers as auditor for FY2026 approved with 32.5M for, 627K against.","Advisory vote on executive compensation passed with 27.1M for, 4.3M against, 328K abstentions.","Broker non-votes on director election and say-on-pay were ~1.44M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130519,"accession_number":"0000730464-25-000033","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem reports Q1 fiscal 2026 results; specific figures not available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued on Oct 30, 2025 covering first quarter fiscal 2026 results.","No financial details (revenue, EPS, guidance) provided in the extracted filing text.","Filing under Item 2.02; press release furnished as Exhibit 99.1 but content not included.","Investors should refer to the full press release for quantitative results."],"consensus_eps_estimate":null,"consensus_eps_actual":1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":462288000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130518,"accession_number":"0000730464-25-000029","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dr. Karen Cox to retire as President of Chamberlain University, Adtalem's nursing school","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Karen Cox retiring after nearly 40-year healthcare career; led Chamberlain since 2018.","Chamberlain serves ~40,000 students online and across 24 campuses; largest nursing school in US.","Adtalem engaged Spencer Stuart for external search; Cox to transition once successor selected.","Cox previously served as president of American Academy of Nursing (2017-2019) and 30 years at Children's Mercy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147072,"accession_number":"0001558370-25-010778","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Adtalem FY2025 revenue $1.79B (+12.9%), adj EPS $6.67 (+33%); FY2026 guidance $7.60-$7.90 adj EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $457.1M (+11.5%), total enrollment 91,780 (+10.2% YoY).","FY2025 adj EPS $6.67 vs $5.01 prior year; adj EBITDA $459.7M (+21.8%).","FY2026 guidance: revenue $1,900-$1,940M, adj EPS $7.60-$7.90.","Increased revolver by $100M to $500M, maturity to Aug 2030, reduced pricing.","New $150M share repurchase authorization through May 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":6.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1788290000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147071,"accession_number":"0001558370-25-009324","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CEO Stephen Beard adopts 10b5-1 plan to sell up to 108,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chairman/CEO Beard entered 10b5-1 plan to sell up to 108,000 shares of common stock.","Sales require minimum price thresholds at a premium to current trading price as of June 10, 2025.","Estimated first sale date not before September 12, 2025; plan ends May 29, 2026.","Beard already exceeds company stock ownership guidelines; plan does not affect compliance.","Trades will be disclosed via Form 144 and Form 4 filings with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165608,"accession_number":"0000730464-25-000007","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q3 FY2025 EPS $1.59 ($1.92 adj.), revenue $466.1M +12.9%; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $466.1M (+12.9% YoY); diluted EPS $1.59 (adj. $1.92, +28% YoY); net income $60.8M.","Total enrollment up 9.8% to 94,223; Chamberlain +6.8%, Walden +13.5%, Med/Vet +1.2%.","Completed $300M share repurchase program; new $150M authorization through May 2028.","FY2025 guidance raised: revenue $1,760-1,775M, adj. EPS $6.40-$6.60 (28-32% YoY growth).","Adjusted EBITDA $127.8M (+19.3% YoY); margin 27.4% vs 25.9% prior year."],"consensus_eps_estimate":1.609,"consensus_eps_actual":4.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":1331184000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165607,"accession_number":"0000730464-25-000005","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adtalem authorizes $150M new buyback; completes $300M prior program, returns $763M since 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $150M share repurchase program, expiring May 2028.","Prior $300M buyback program completed on May 5, 2025, ahead of original Jan 2027 expiry.","Since Feb 2022, $763M returned to shareholders; shares outstanding reduced by 28% at avg $49/share.","About 36M shares outstanding as of May 5, 2025.","Q3 FY2025 earnings call scheduled for May 8, 2025 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183229,"accession_number":"0001558370-25-000543","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q2 FY2025 EPS $1.98 ($1.81 adjusted), revenue up 13.9%, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $447.7M (+13.9% YoY); GAAP net income $75.9M ($1.98 diluted EPS).","Adjusted EPS $1.81 (+47.2% YoY); adjusted EBITDA $125.0M (+35.1% YoY).","Total enrollment 91,264 (+11.6% YoY); Chamberlain +11.5%, Walden +13.2%.","FY2025 guidance raised: revenue $1,730M-$1,760M, adjusted EPS $6.10-$6.30.","Repurchased $38M shares in Q2; repaid $100M term loan B; net leverage 1.1x."],"consensus_eps_estimate":1.5632,"consensus_eps_actual":3.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":865129000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199811,"accession_number":"0001558370-24-015853","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Adtalem CEO Steve Beard elected Chairman; Q1 enrollment up 11.2% to 90,000+","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Beard, President and CEO, unanimously elected Chairman of the Board effective Nov. 13, 2024.","Michael Malafronte transitions from Chairman to Lead Independent Director, Chair of Compensation Committee.","Q1 FY2025 total enrollment surpassed 90,000, up 11.2% YoY; ~90% enrolled in healthcare programs.","Annual meeting results: all 10 directors elected, PwC ratified as auditor, say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199810,"accession_number":"0001558370-24-013845","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q1 FY2025: Revenue up 13.2%, adj. EPS $1.29 (+38.7% YoY); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $417.4M (+13.2% YoY); net income $46.2M vs $10.6M prior year; adj. EPS $1.29 vs $0.93.","Total enrollment 90,140, up 11.2% YoY; Chamberlain +11.7%, Walden +12.2%, Medical/Vet -0.7%.","FY2025 guidance raised: revenue $1,690M-$1,730M; adj. EPS $5.75-$5.95 (14.5%-18.5% growth).","Repurchased $34M of shares; $178M remaining under $300M buyback program through Jan 2027.","Repriced $253M Term Loan B, reducing interest rate by 75 bps; net leverage 1.0x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":417400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215831,"accession_number":"0001558370-24-012476","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["8.01","2.03","9.01","1.01"],"status":"ready","headline":"Adtalem Global Education reprices term loans, reducing interest margin by 0.75%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended Credit Agreement reduces interest rate margins by 0.75% and removes leverage-based pricing grid.","New interest rate: Term SOFR plus 2.75% or alternate base rate plus 1.75%, at company's option.","Amendment affects all outstanding term loans under the August 12, 2021 Credit Agreement.","Transaction closed August 21, 2024; administrative agent is Morgan Stanley Senior Funding, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215830,"accession_number":"0001558370-24-011090","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q4 rev $409.9M (+12.4% YoY); FY25 EPS guidance $5.60-$5.85 above prior projections","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY24 diluted EPS $3.39; adjusted EPS $5.01 (+19% YoY). Revenue $1,584.7M (+9.2% YoY).","Total enrollment up 10.0% YoY to 83,321; Chamberlain +10.4%, Walden +11.3% for 6th and 4th straight quarters.","FY25 guidance: revenue $1,660M-$1,700M (5-7.5% growth); adjusted EPS $5.60-$5.85 (12-17% growth).","Repurchased $261M shares; repaid $50M Term Loan B, repriced remaining $253M at 50 bps lower rate; net leverage 1.2x.","Initiating Kansas City expansion with 24th Chamberlain location for ~550 students."],"consensus_eps_estimate":null,"consensus_eps_actual":3.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":1584652000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235260,"accession_number":"0001558370-24-006546","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q3 revenue up 11.8% YoY; adjusted EPS $1.50, raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $412.7M (+11.8% YoY); total enrollment 85,809 (+7.8% YoY).","GAAP diluted EPS $0.93; adjusted EPS $1.50 (+32.7% YoY).","Adjusted EBITDA $107.1M (+24.6% YoY); margin 25.9% vs 23.3%.","FY2024 guidance raised: revenue $1,560-$1,580M, adjusted EPS $4.80-$5.00.","Chamberlain enrollment +9.0% (5th straight growth quarter); Walden enrollment +8.4%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":1174745000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235259,"accession_number":"0000730464-24-000004","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K/A","filed_at":"2024-04-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adtalem finalizes separation agreement with ex-President Danaher; details severance terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Severance of $1,014,390 (1x salary + 70% MIP target) payable in 12 monthly installments.","FY23 MIP award set to 0% by CEO; no FY23 payout and no pro-rated FY24 MIP.","Unvested LTI awards (RSUs, PSUs, options) will continue to vest per award agreements.","One-time lump sum of $14,513 for COBRA subsidy for dependents; counsel fees of $62,000 paid.","Standard noncompete, nonsolicitation, confidentiality covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253096,"accession_number":"0001157523-24-000163","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adtalem counters Safkhet Capital short report, refutes claims on enrollment, graduation rates, and financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total enterprise enrollment up 6% YoY as of Dec 31, 2023; Chamberlain up 7%, Walden up 8%.","Chamberlain four-year graduation rate for all full-time students is 77% vs. national average of 49%.","Walden acquisition goodwill tested in May 2023; no impairment identified.","Company expects all degree programs to pass Department of Education gainful employment rule.","Calls Safkhet report a 'short and distort' scheme; denies material risk from borrower defense or 90/10 rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253095,"accession_number":"0001157523-24-000136","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Adtalem Q2 revenue +8.4% to $393.2M, raises FY guidance; short seller report disclosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $393.2M (+8.4% YoY); total enrollment 81,772 (+6.2%); Chamberlain enrollment +6.6%, Walden +7.9%.","Diluted EPS $0.98; adjusted EPS $1.23 (+5.1% YoY); adjusted EBITDA $92.6M (+2.2%); margin 23.5%.","FY2024 guidance raised: revenue $1,520-$1,560M (from $1,470-$1,530M); adj. EPS $4.55-$4.75 (from $4.25-$4.45).","Completed $300M buyback; new $300M authorization through Jan 2027; repaid $50M Term Loan B; repriced $253M at 50bps lower; net leverage 1.5x.","Filed risk factor re: short seller report published Jan 30 alleging misconduct; share price impacted; may lead to litigation/regulatory probes."],"consensus_eps_estimate":null,"consensus_eps_actual":1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":762087000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253094,"accession_number":"0001157523-24-000084","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adtalem authorizes $300M new share repurchase program through Jan 2027; completes prior $300M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $300M share buyback authorization expires Jan. 16, 2027; purchases may be open market or privately negotiated.","Prior $300M Feb 2022 program completed on Jan. 16, 2024, repurchasing 11.6M shares at avg $39.85.","Since Feb 2022, shares outstanding reduced by 23%; ~39.3M shares outstanding as of Jan. 16, 2024.","CEO Steve Beard cites confidence in growth strategy and robust cash flow supporting capital allocation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253093,"accession_number":"0001157523-24-000041","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adtalem appoints Betty Vandenbosch to board, effective Jan 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Betty Vandenbosch appointed as independent director, will serve on Academic Quality Committee.","Vandenbosch brings 30 years of EdTech and academic leadership, including Coursera (SVP/Chief Content Officer) and Purdue Global chancellor.","Appointment effective January 8, 2024; compensation same as other non-employee directors per proxy filed Oct 2023.","Her background includes roles at Kaplan University (president 2015-2018) and Case Western University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270552,"accession_number":"0001157523-23-001784","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Adtalem amends bylaws to adopt universal proxy rules and update advance notice provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws require stockholders using universal proxy to certify compliance with SEC Rule 14a-19.","Stockholders soliciting proxies must use a proxy card color other than white.","Advance notice for stockholder proposals now due 120-150 days before prior year's annual meeting anniversary.","Bylaw changes effective November 27, 2023, after periodic review and SEC universal proxy rule updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270551,"accession_number":"0001157523-23-001720","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adtalem shareholders elect 10 directors and approve all proposals at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with 36.9M-37.1M votes FOR each, no close contests.","Ratification of PwC as auditor for 2024 approved with 37.7M FOR vs 0.8M AGAINST.","Advisory say-on-pay approved with 36.3M FOR; shareholders selected annual frequency for future votes.","Amendment to Restated Certificate to add Delaware officer exculpation passed with 33.6M FOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270550,"accession_number":"0001157523-23-001560","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q1 FY2024: revenue $368.8M, adjusted EPS $0.93; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $10.6M ($0.25 diluted EPS); adjusted EPS $0.93, up 3.3% YoY.","Total enrollment 81,073 (+1.9% YoY); Chamberlain up 5.2%, Walden up 0.5%.","FY2024 guidance raised: revenue $1,470-1,530M; adjusted EPS $4.25-4.45.","Repurchased $92M of shares under $300M board authorization; net leverage 1.3x.","Medical/Vet segment revenue down 3.8%, enrollment down 7.5% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":368845000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287489,"accession_number":"0001157523-23-001399","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adtalem announces departure of President of Medical & Veterinary segment Dr. John Danaher effective Sep 15, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. John Danaher, President of Adtalem Medical & Veterinary, will leave effective September 15, 2023.","Company is actively searching for a replacement; terms of departure to be disclosed in an amended 8-K within four business days.","No other details regarding the departure or transition were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287488,"accession_number":"0001157523-23-001317","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem FY2023 adjusted EPS $4.21, up 35% YoY; raises FY2024 guidance low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 adjusted EPS $4.21 (+35% YoY); GAAP EPS $2.05; Q4 adjusted EPS $1.03.","FY2023 revenue $1,450.8M (+5.0%); Q4 revenue $364.6M (+1.1%).","Total enrollment 75,735 (-2.5% YoY), improved sequentially; Chamberlain +1.2%.","FY2024 guidance: revenue $1,460-1,520M; adj. EPS $4.20-4.40 (low end raised $0.05).","FY2023 adj. EBITDA $343.4M (+4.5%); gross debt reduced $151M; net leverage 1.3x."],"consensus_eps_estimate":null,"consensus_eps_actual":2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1450826000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307669,"accession_number":"0001157523-23-001007","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adtalem posts investor presentation for 2023 Investor Day; no specific financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an investor presentation on June 20, 2023, for its 2023 Investor Day.","Presentation filed as Exhibit 99.1 but no substantive financial or strategic figures are included in the filing.","Filing under Item 7.01 Regulation FD; information is furnished, not filed.","Forward-looking statements refer to Walden acquisition synergies but provide no new specific guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307668,"accession_number":"0001157523-23-000998","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adtalem unveils Growth with Purpose strategy and long-term financial targets through FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms FY2023 guidance: revenue $1.40B-$1.45B, adjusted EPS $4.05-$4.20.","FY2024 guidance: revenue $1.46B-$1.52B, adjusted EPS $4.15-$4.40.","Long-term targets: FY2025 revenue growth 4-6% YoY, adj. EPS growth 10-15%; FY2026 revenue growth 5-8%, adj. EPS growth 13-18%.","Strategy focuses on market scale, operational excellence, student experience, and healthcare partnerships.","Investor Day held at Chamberlain University Chicago campus on June 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307667,"accession_number":"0001157523-23-000683","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q3 revenue $369.1M (+1.3% YoY); adjusted EPS $1.13 (+34.5%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS $1.13 up 34.5% YoY; GAAP EPS $1.00 vs $7.04 prior year on prior-year gain.","Revenue $369.1M; total enrollment 79,586 (-3.1% YoY, 100 bps sequential improvement).","Chamberlain revenue +5.0% to $149.7M, enrollment +2.0%; Walden revenue -4.5%, enrollment -7.9%.","FY 2023 guidance narrowed: revenue $1,400M-$1,450M, adj. EPS $4.05-$4.20.","Repurchased $48M in shares during Q3 under $300M buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":1086185000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326647,"accession_number":"0001157523-23-000155","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q2 revenue down 2.1% but adjusted EPS up 56%; margins expand, guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $363.3M (-2.1% YoY); diluted EPS $0.52 vs $0.36; adjusted EPS $1.17 vs $0.75 (+56%).","Adjusted operating margin 21.9% (up from 18.9%); adjusted EBITDA $92.1M (+7%), margin 25.4% (up 220 bps).","Gross debt reduced by $50M (6.6% decrease from prior quarter end).","Walden enrollment down 7.8%; segment revenue $131.9M (-6.2% YoY). Chamberlain enrollment -0.8%, revenue +1.7%.","Reaffirmed FY2023 guidance: revenue $1.38B-$1.45B, adjusted EPS $3.95-$4.20."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":717861000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344360,"accession_number":"0001157523-22-001606","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Adtalem board elects Michael Malafronte as Chairman, succeeding Lisa Wardell","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Malafronte elected Chairman effective Nov. 9, 2022, succeeding Lisa Wardell who continues as director.","Malafronte has been independent director since 2016; previously chaired compensation committee.","Board reconstituted committee chairs: Georgette Kiser (Academic Quality), William Burke (Audit), Kenneth Phelan (Comp), Donna Hrinak (External Relations), Sharon O'Keefe (Nominating).","Annual meeting approved all 11 directors, ratified PwC as auditor (42.2M for), and passed say-on-pay (39.2M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344359,"accession_number":"0001157523-22-001521","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q1 revenue $354.6M (+22.7%); adjusted EPS $0.88 (+151%); margins expand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $354.6M up 22.7% YoY; diluted EPS $0.05 vs loss of $1.17; adjusted EPS $0.88 up 151.4%.","Adjusted operating income $65.1M up 78.7%; adjusted EBITDA $82.1M up 62.6%; margin expanded to 23.1% from 17.5%.","Gross debt reduced by $101M (11.7%) in Q1.","Segment: Chamberlain revenue flat, enrollment -4%; Walden enrollment -9.2%; Medical/Vet enrollment +3.4%.","Reaffirmed FY2023 guidance: revenue $1,380M-$1,450M, adjusted EPS $3.95-$4.20."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":354559000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360870,"accession_number":"0001157523-22-001106","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q4 revenue +61.6% to $361.2M; FY2022 adj. EPS $3.24 (+40% YoY); FY2023 guidance $3.95-$4.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $361.2M (+61.6% YoY); GAAP EPS $0.18 flat; adjusted EPS $1.31 vs $0.48 YoY.","FY2022 GAAP EPS $6.57; adjusted EPS $3.24, up 40% YoY; adjusted EBITDA margin 24.0% vs 22.4%.","Gross debt reduced by $394.1M in Q4 (31.4%); balance sheet strengthened.","FY2023 guidance: revenue $1.38B-$1.45B; adjusted EPS $3.95-$4.20.","Chamberlain enrollment -5.8% YoY; Walden enrollment -9.5%; Medical/Vet enrollment +3.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":6.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1387122000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379994,"accession_number":"0001157523-22-000732","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adtalem appoints Liam Krehbiel as independent director, effective June 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William 'Liam' Krehbiel appointed as independent board member, effective June 6, 2022.","Board size increased from 11 to 12 directors.","Krehbiel is founder/CEO of Topography Hospitality and founder/chair of A Better Chicago.","He will stand for re-election at 2022 annual meeting; compensation same as other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379993,"accession_number":"0001157523-22-000674","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adtalem Global Education appoints Michael Betz as President of Walden University","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Betz appointed President of Walden University effective May 17, 2022; responsible for strategy and operations.","Previously partner at McKinsey & Co. (2017-2022); led higher education and growth transformation practices.","Employment terms: $540,000 base salary, 75% cash bonus target, 100% LTI equity grants, one-time RSU grant of $350,000.","No family relationships with officers/directors; no material interests in transactions requiring disclosure.","Betz succeeds Roger McKinney who remains CFO; no departure of prior president mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379992,"accession_number":"0001157523-22-000571","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Q3 EPS $7.09; raises FY22 adjusted EPS guidance to $3.15-$3.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $365.6M (+58.8% YoY); adjusted diluted EPS from cont. ops $0.87 vs $0.60 prior year.","Completed $1B divestiture of Financial Services segment; used $770M to reduce debt by 46.7%.","Repurchased 4.7M shares for $150M; board authorized $300M share repurchase over 36 months.","FY22 guidance: adjusted revenue $1.35B-$1.39B; adjusted diluted EPS raised to $3.15-$3.35.","Chamberlain op income +2.4% despite revenue decline; Medical/Vet adjusted op income +30.1%."],"consensus_eps_estimate":null,"consensus_eps_actual":6.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1025891000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379991,"accession_number":"0001157523-22-000435","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adtalem appoints Manjunath Gangadharan as VP and Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective April 18, 2022; Gangadharan will serve as principal accounting officer, reporting to CFO Robert J. Phelan.","Base salary $325,000; annual cash bonus target 50% of base; LTI target 50% of base.","One-time RSU grant of $175,000 vesting 25% annually over 4 years; sign-on cash bonus of $75,000 in 2022 installments.","Previously VP, Corporate Controller at Culligan International (since 2021); prior CAO at Groupon (2020-2021).","No family relationships or material interest in any transaction required to be disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379990,"accession_number":"0001157523-22-000415","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adtalem retires $373.3M of 5.500% Notes, 46.67% of outstanding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$373,333,000 of 5.500% Senior Notes due 2028 validly tendered and accepted for purchase.","Tendered notes represent 46.67% of the outstanding principal amount of the Notes.","Purchase price: 100% of principal ($1,000 per $1,000) plus accrued interest up to April 11, 2022.","Offer expired at 5:00 p.m. ET on April 8, 2022, pursuant to Asset Sale Offer launched March 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398146,"accession_number":"0001157523-22-000332","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Adtalem offers up to $373.3M for 5.5% notes due 2028; enters $150M ASR with Morgan Stanley","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offer to purchase up to $373.3M of 5.500% Senior Notes due 2028 at 100% of principal plus accrued interest.","Offer expires April 8, 2022; funded with proceeds from financial services segment divestiture.","Entered $150M accelerated share repurchase with Morgan Stanley; received initial ~4.7M shares.","Board also authorized up to $300M open market repurchases over 36 months (previously announced March 1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398145,"accession_number":"0001157523-22-000316","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Adtalem completes $1B sale of Financial Services segment; plans $770M debt paydown","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold ACAMS, Becker Professional Ed, and OnCourse Learning to Wendel Group & Colibri Group for $1B cash.","Net proceeds ~$820M; company will deploy ~$770M to pay down debt within 30 days.","Annualized interest expense savings of approx. $40M from debt reduction.","Pro forma balance sheet shows long-term debt reduced from $1.6B to $849M as of Dec 31, 2021.","Transaction sharpens focus on healthcare education; CEO cites strengthened balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398144,"accession_number":"0001157523-22-000276","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adtalem announces $150M ASR, $300M buyback authorization; plans $770M debt paydown from divestiture","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$150M accelerated share repurchase (ASR) program funded with existing cash.","Board authorizes $300M open market share repurchases over next 36 months.","Approximately $770M of $820M net proceeds from divestiture to pay down debt.","Company expects annualized interest expense savings of ~$40M from debt paydown.","Financial services divestiture expected to close by March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398143,"accession_number":"0001157523-22-000219","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"DOE discharges loans for 1,800 former DeVry students; Adtalem faces potential indemnification claims","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DOE announced on Feb 16, 2022 it will discharge federal student loans for ~1,800 former DeVry University students under borrower defense to repayment (BDR) program.","Adtalem sold DeVry University to Cogswell in 2017 and agreed to indemnify DeVry for certain losses up to $340M, including BDR claims.","Adtalem states it has not been contacted by DOE and lacks specifics on how the loans were adjudicated or if borrowers already received relief.","Previously disclosed BDR-related matters have consumed a portion of the $340M indemnification cap, but Adtalem cannot yet quantify this new impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398142,"accession_number":"0001558370-22-000905","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adtalem restates historical financials reflecting Financial Services segment as discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2021 continuing ops GAAP net income $70.3M, non-GAAP net income $119.2M; diluted non-GAAP EPS $2.31.","FY2020 continuing ops GAAP net income $219.9M, non-GAAP net income $95.8M; diluted non-GAAP EPS $1.77.","Q1 FY2022 continuing ops GAAP net loss $77.2M; non-GAAP net income $17.6M (diluted $0.35).","Segment non-GAAP op income FY2021: Chamberlain $128.9M, Medical/Vet $67.9M, Home Office loss $40.2M.","Discontinued ops net income: FY2021 $6.1M, FY2020 loss $305.7M (incl. loss on disposal)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398141,"accession_number":"0001157523-22-000157","cik":730464,"company_name":"Covista Inc.","ticker":"CVSA","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adtalem Global Education Reports Fiscal Q2 2022 Results, Revises Full-Year Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue rose 58.4% to $371.2M, driven by the Walden acquisition; diluted EPS fell to $0.36 from $0.44.","Adjusted diluted EPS from continuing operations was $0.75, up from $0.61; operating income excluding special items rose 70% to $70.2M.","Pending sale of Financial Services segment to a consortium of Wendel Group and Colibri Group to sharpen healthcare focus.","Full-year fiscal 2022 revenue guidance revised to $1.35B–$1.39B, adjusted EPS to $2.90–$3.10 from continuing operations.","COVID-19 headwinds, especially Omicron, continued to impact post-licensure nursing enrollments at Chamberlain and Walden."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":660268000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4170144854.0397525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-08T23:59:59+00:00|398141"}